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Abstract
Background: Many hepatobiliary centres are increasingly utilizing thermocoagulative devices such as
bipolar-radiofrequency ablation (B-RFA). Compared with monopolar-radiofrequency ablation (M-RFA),
B-RFA does not require grounding pads, thereby avoiding dermal burn injuries, and does not position
probes directly into the tumour but rather on the perimeter. Additionally, B-RFA can precoagulate
parenchyma to assist in hepatic resection. Herein, we report our early experience using B-RFA.
Methods: A retrospective review identified 68 patients who underwent M-RFA or B-RFA between June
2004 and September 2010 in an academic centre. Peri-operative metrics were analysed.
Results: M-RFA was used to treat 30 patients, whereas B-RFA was used for 17 patients. There were no
differences in peri-operative metrics, survival or disease recurrence between M-RFA and B-RFA. Seven-
teen additional patients underwent B-RFA precoagulation during laparoscopic resection (segmentectomy
in eleven patients and multi-segmental resection in six patients). Four patients with multifocal disease
underwent procedures that combined B-RFA with resection.
Conclusions: The early experience utilizing B-RFA demonstrates equivalency to M-RFA with respect to
peri-operative metrics and survival. Moreover, B-RFA can be utilized to precoagulate tissue during a
planned resection, making it not only a useful tool for tumour therapy but also a useful adjunct during
surgical resections.
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Introduction
Radiofrequency ablation (RFA) has undergone a refinement of its
indications and techniques for the treatment of malignant liver
tumours since its description in 1990.1 The efficacy of ablation is
dependent upon multiple factors, including tissue characteristics
such as cirrhosis, hepatic steatosis, vascular perfusion and tumour
type.2 These factors cause variability in the extent of ablation,
leading some to question the ability to achieve complete ablation
in tumours greater than 3 cm given recurrence rates as high as
34%.3–5
In the United States, most centres continue to use conventional
monopolar-RFA (M-RFA) devices, which employ a single-needle
electrode that delivers an electrical current at 400–500 kHz to
create a core zone of ablation at the tumour site which extends
radially into the adjacent tissue. Importantly, M-RFA requires the
use of grounding pads which are placed on the patient’s thighs or
back to complete the electrical circuit. The single-needle tip elec-
trode can reach target temperatures of over 100°C, but is prone to
rapid charring thereby increasing tissue impedance which limits
thermal energy distribution. While M-RFA is sufficient for small
tumours (<2.0 cm), larger tumours require expandable electrodes
(i.e. longer tines) and longer coagulation times to increase
the radius of ablation.3–5 M-RFA is also highly susceptible to ‘heat
sinks,’ or convective heat loss from adjacent hepatic vessels.
Experimental studies have determined that the presence and
number of adjacent vessels directly impacts the efficacy and
size of ablation.6 Other limitations of this modality include
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myoglobinaemia, cardiac arrhythmias, increased total operative
time, risk of incomplete tumour ablation and thermal skin injury
underneath the grounding pads.7–9 The incidence of serious
dermal complications ranges from 5–33% for first degree burns
and 0.3–3.2% for second- and third- degree burns.10
In an effort to overcome the shortfalls of M-RFA, many centres
are increasingly employing other thermocoagulative devices to
treat liver tumours, including microwave ablation and bipolar-
RFA (B-RFA).11,12 B-RFA utilizes dual probes which are placed
ideally in healthy parenchyma surrounding the tumour to deliver
a 440–480 kHz energy field in a controlled fashion between the
probes. Depending on the type of B-RFA probes used, either a
rounded rectangular or a rounded cube ablation distribution is
achieved to a reliable tissue ablation area up to 7 cm.2 Referred to
as a ‘line of sight’ delivery system,12 B-RFA is completely different
than M-RFA which requires direct penetration of the targeted
tumour (Fig. 1). The advantage of ‘line-of-sight’ energy delivery is
that it avoids the rapid charring effect around the electrode tip
thereby effectively ablating larger tumour volumes.
In animal studies, B-RFA has been shown to be safe and effec-
tive and can also be used with the ‘overlapping’ technique to
increase the efficacy and size of the burn zone.13 Moreover, B-RFA
is less prone to conductive ‘heat sinks,’ and in fact traps heat
between probes resulting in higher temperatures, more effective
cellular destruction and a larger zone of ablation.14 Theoretically,
this form of RFA energy is less likely to result in necrotic liver
parenchyma thereby decreasing the incidence of septic complica-
tions when compared with monopolar ablations that are prone to
inaccurate energy release.15,16
In addition to its role as a stand-alone treatment for liver
tumours, RFA can also be used as an adjunctive tool during liver
resections. RF energy is used to pre-coagulate liver tissue before
parenchymal transection as a means of reducing intra-operative
blood loss and post-operative morbidity.17 While both M-RFA
and B-RFA energy sources have been expanded to be used in
hepatic resections, B-RFA is more widely accepted for this indica-
tion.17,18 Currently, various commercial B-RFA electrode systems
are available which are designed specifically to perform liver
resections.15,19
The purpose of the present study was to compare the results of
M-RFA with B-RFA in the treatment of liver tumours, and also to
evaluate the feasibility and safety of dual-probe B-RFA technology
for assisting in laparoscopic hepatic resections.
Methods
A retrospective review of a prospectively-maintained database
identified 68 patients at a single centre who underwent laparo-
scopic M-RFA, laparoscopic B-RFA or B-RFA pre-coagulation
before laparoscopic liver resection by a single surgeon between
June 2004 and September 2010. Peri-operative and follow-up
analysis was stratified by ablation type and procedure. Statistical
comparison of demographic and peri-operative metrics was per-
formed using the Mann–Whitney U-test for continuous data and
Fisher’s exact test for categorized data. A P-value of <0.05 was
considered significant. Follow-up survival comparison was per-
formed using Kaplan–Meier analysis. Statistical analysis was per-
formed using GraphPad Prism® 5.0 (GraphPad Software, Inc., La
Jolla, CA, USA).
Surgical technique for laparoscopic M-RFA, B-RFA
and/or resection
All operations were performed under general anaesthesia with
patients in either the supine or left lateral decubitus position.
Pneumoperitoneum was induced to 15 mmHg and a 30 degree
laparoscope was utilized in all procedures. The liver was fully
mobilized laparoscopically off of the retroperitoneum and dia-
phragm to access the tumour-bearing segments. Tumours were
(a) (b)
Figure 1 Monopolar (M-) vs. bipolar (B-) radiofrequency ablation (RFA): schematic showing differences between monopolar (a) and bipolar (b)
ablation. Monopolar probes require single probe insertion directly into the tumour, allowing for thermocoagulation of tissue adjacent to
deployable tines. Bipolar ablation requires placement of dual probes in the perimeter of the tumour, and the current stream travels between
the probes
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identified and margins characterized using an intra-operative lap-
aroscopic ultrasound probe (Aloka America, Wallingford, CT,
USA). The StarburstTM (RITAMedical Systems Inc., Fremont, CA,
USA) multiple needle array (2–7 cm) device was used for all
tumours treated byM-RFA, with device-energy settings applied as
directed by the manufacturer. Multiple overlying ablations were
done to optimize tumour destruction.
All tumours treated by B-RFA were performed using the InCir-
cleTM (RFA Medical, Inc., Fremont, CA, USA) parallel electrode
system, which does not require grounding pads. Although this
device is pre-packaged with the probes held in parallel by a 3-cm
bracket, the majority of operations were done with the bracket
completely removed allowing greater freedom of adjustment to
the desired ablation zone. For the purpose of the present study, the
25-cm-long probes were used with each needle deploying six cir-
cular, planar-oriented electrodes spanning up to 3 cm (Fig. 2a).
This device is designed to be used percutaneously and guided by
either laparoscopy or axial imaging (Fig. 2b).
An important consideration when using this device is adequate
mobilization of the liver – especially the right side. Full mobiliza-
tion of the liver allows precise and controlled protection of the
diaphragm and viscera from thermal injuries by stray needle
probes. The ability to manipulate the liver in various directions
and planes is also important to provide broad access for needle
probe placement. The technique adopted to maximize the zone of
ablation consisted of at least three, 90-degree overlapping abla-
tions with the needle probes deployed vertically (i.e. along the
sides of tumour). The power setting for each ablation was 150
watts, with the target temperature set at 105°C. After the tumour
ablations were completed along a horizontal plane moving later-
ally to medially across the liver, the needle probes were turned 90
degrees so that the tines were oriented horizontally (i.e. along the
top and bottom of the tumour). Threemore overlapping ablations
were then completed in the same plane. The initial ablation gen-
erally took approximately 5 min to reach the target temperature
(for 3-cm tumours). As the tissue/tumour desiccates, the current
impedance rises quickly so that subsequent overlapping ablations
require less time. Importantly, no RFA ablations were done in
areas near the hilum of the liver to avoid vascular or biliary
injures. The overall tumour ablation times necessary depended on
tumour size, liver tissue type and mode of RF energy used.
All laparoscopic resections using a pre-coagulation technique
were done with the B-RFA InCircleTM device (Fig. 3a). In selected
operations, inflow control (Pringle manoeuver) was used
depending on the magnitude of resection. In general, the tech-
niques used for laparoscopic hepatic resections were similar to
those used in open resections. After the tumour(s) had been
fully evaluated by ultrasonography, the line of transection was
marked on the liver surface using electrocautery. The InCircleTM
needles were introduced in parallel approximately 1 to 1.5 cm
apart and the circular tines deployed. A 2–3 cm zone of ablation
was generated accounting for sufficient tumour margins while at
the same time avoiding injury to critical intra-hepatic structures,
viscera and/or the diaphragm. All parenchymal division was
done using the Gyrus (Olympus Corp., Tokyo, Japan) bipolar
cutting forceps (Fig. 3b).
Radiological follow-up protocol
For hepatocellular carcinoma (HCC), solid benign lesions and
non-colorectal adenocarcinoma, patients were followed with
triple-phase, 5-mm cut computed tomography (CT) scans at
3-month intervals post-operatively for the first 2 years, 6-month
intervals for the following 2 years and then on a yearly basis. An
incomplete ablation was recorded if the first post-RFA CT showed
a persistent hypervascular area suspicious for residual disease.
Local recurrence was defined by a hypervascular region located
within the RFA zone not previously seen on surveillance CT scans.
In several patients, perfusion artefacts were noted in the radiology
reports that were indeterminate for tumour recurrence. For the
purpose of the present study, all of these patients were considered
to have local recurrence. The calculated local recurrence rate
included patients with incomplete ablations, those with docu-
mented recurrence and those with indeterminate lesions.
Figure 2 The InCircle™ (RFA Medical, Inc., Fremont, CA, USA) parallel electrode system for bipolar radiofrequency ablation (B-RFA).
Twenty-five-cm needle probes deploy six circular, planar-oriented electrodes spanning up to 3 cm (a). This device is designed to be used
percutaneously, is guided by either laparoscopy or axial imaging (b) and does not require the use of grounding pads
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Results
Comparison of M-RFA to B-RFA
M-RFA alone was used to definitively treat 30 patients, whereas
B-RFA alone was used for 17 patients with contraindications to
resection or as bridge therapy towards liver transplantation.
Demographics and peri-operative factors are shown in Table 1.
Major complications using B-RFA included two instances of a
pneumothorax and one patient with hepatic decompensation,
whereas M-RFA included RFA skin burns in two patients and
hepatic decompensation in one; there were no deaths in either
group. There were no differences in local or overall recurrence,
time to recurrence, and overall and disease-free survival between
the two groups (Fig. 4).
Laparoscopic liver resection with
B-RFA pre-coagulation
Seventeen patients underwent laparoscopic liver resections using
B-RFA energy for coagulation before parenchymal transection
(Table 2), including anatomic segmental resections in 11 patients
and multi-segmental resection or hemihepatectomy in six
patients. In four patients with multiple tumours, B-RFA energy
was used in combination to ablate some tumours and resect
Figure 3 Parenchymal thermocoagulation prior to resection. The InCircle™ (RFA Medical, Inc., Fremont, CA, USA) bipolar radiofrequency
ablation (RFA) probes were used to pre-coagulate liver tissue along the plane of resection (a). Parenchymal division was performed using
the Gyrus cutting bipolar cutting forceps (Olympus Corp., Tokyo, Japan) (b)
Table 1 Comparison of demographic and peri-operative outcomes between monopolar- (M-RFA) and bipolar-radiofrequency ablation
(B-RFA)
B-RFA M-RFA P-value
Patients 17 30
Demographics
Age, years median (range) 63 (55–81) 57 (47–82) 0.00192
Gender (M : F) 15 : 2 30 : 0
Disease Malignant (HCC) – 15
Benign (adenoma) – 2
Malignant (HCC) – 30
MELD median (range) 8 (5–13) 8 (4–13) 0.402
Tumour size, cm median (range) 3 (1.2–5.0) 3 (1.8–6.8) 0.541
Peri-operative outcomes
Laparoscopic 16/17 25/30 0.390
Cholecystectomy 8/17 5/30 0.0409
Time, min median (range) 275 (152–436) 175 (85–550) <0.001
Blood loss, mL median (range) 100 (10–500) 75 (5–300) 0.152
Hospitalization, days median (range) 7 (3–18) 5 (2–9) 0.0150
Complications32 Grade 2 = 1 (PNA)
Grade 3 = 2 (PTX)
Grade 4 = 1 (hepatic insufficiency)
Grade 2 = 2 (arrhythmia)
Grade 3 = 2 (RFA burns)
Grade 4 = 1 (GI bleed)
Major complications 3/17 3/30 0.702
MELD, model for end-stage liver disease; HCC, hepatocellular carcinoma; PNA, pneumonia; PTX, pneumothorax; GI, gastrointestinal.
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others. Major complications occurred in three patients: two suf-
fered a clinically significant pulmonary embolism and one death
occurred from liver failure as a result of portal vein thrombosis 1
week after resection.
Discussion
Given that a majority of patients with HCC are not candidates for
or unable to tolerate a surgical resection, non-surgical and
minimally-invasive approaches are attractive options for treat-
ment or bridge to transplantation.20,21 In the United States, RFA is
among the most frequently used modality, with thousands of
operations done yearly. Although M-RFA technology has signifi-
cant limitations, it has been extensively described and is histori-
cally the most widely used thermal ablative method. In an effort to
overcome the limitations of M-RFA, other thermal energy systems
have been introduced for destruction of liver tumours. B-RFA
energy systems have the advantage of delivering a stronger current
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Figure 4 Overall- and disease-free survival over a median follow-up of 20.6 months for bipolar-radiofrequency ablation (B-RFA) (range,
3.0–39.6months) and 31.5months formonopolar-radiofrequency ablation (M-RFA) (range, 1.4–75.9months). Therewas nodifference between
B-RFA and M-RFA with respect to rates of local recurrence (3/17 vs. 8/30, P = 0.733) or overall recurrence (7/17 vs. 14/30, P = 0.982). Median
time to recurrence was also similar between B-RFA and M-RFA (12.6 months, range 3.4–25.1 vs. 12.4 months, range 3.0–44.7; P = 0.933)
Table 2 Demographic and peri-operative outcomes of laparoscopic liver resection utilizing bipolar-radiofrequency ablation (B-RFA) to
pre-coagulate liver parenchyma before transection
Demographics No. of patients 17
Age, years median (range) 60 (42–91)
Gender (M : F) 14 : 3
Disease Malignant = 11
Benign = 2
Metastatic = 4
MELD median (range) 8 (6–15)
Tumour size, cm median (range) 5 (0.5–10.5)
Peri-operative Outcomes Operation Segmentectomy – 11
Multi-segmental – 6
Time, min median (range) 434 (131–830)
EBL, mL median (range) 300 (20–3000)
Hospitalization, days median (range) 7 (3–35)
Complications32 Grade 1 = 1 (ileus)
Grade 2 = 1 (ascites)
Grade 3 = 2 (hepatic insufficiency, biloma)
Grade 4 = 2 (PE)
Grade 5 = 1 (death)
MELD, model for end-stage liver disease; EBL, estimated blood loss.
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density that reduces the need for thermal conduction resulting in
more rapid ablation. Animal studies comparing M-RFA to B-RFA
using the dual needle probe system have shown superiority for the
B-RFAmethod with respect to larger ablation zone, tissue control,
haemostasis and overall efficiency.22 Clinical studies are also
beginning to emerge confirming improved tumour ablation times
and efficacy using bipolar radiofrequency energy in comparison
with M-RFA.12
In the present study, the initial experience with the bipolar
probes demonstrates the efficacy of this device and equivalency to
M-RFA with regard to peri-operative and survival outcomes.
Moreover, B-RFA avoids the complication of skin burns as it does
not require grounding pads. In particular, the InCircleTM device is
unique in that it can also be used to assist in hepatic resections for
parenchymal tissue pre-coagulation. This series demonstrates
certain benefits with the laparoscopic, bipolar approach for
tumour ablation. For all patients, it was possible to perform the
entirety of the ablation laparoscopically without the need for con-
version to laparotomy. While this point may seem trivial, it is
exceedingly important in patients with compromised hepatic
reserve (as in the current patient population described) prone to
wound complications.
As is the case with any new technology, there is an important
learning curve associated with using the InCircleTM B-RFA device.
The surgeon is required to conceptually change the traditional
M-RFA approach to target the tumour. While mastering laparo-
scopic ultrasonography is a prerequisite for successful tumour
ablation regardless of the energy source, the B-RFA method
demands specific thee-dimensional (3-D) spatial planning before
energy delivery. As mentioned, this concept is called ‘line-of-sight’
deployment of the dual electrodes. Planning and developing a 3-D
mental image of the desired ablation zone is necessary because
once the energy is delivered, the targeted tumour is poorly visu-
alized under ultrasonography.
The lack of real-time tumour destruction assessment is one
important limitation of using RFA energy. However, in compari-
son with monopolar techniques, B-RFA tends to be more con-
trolled and faster for similarly-sized tumours. Although reported
M-RFA ablation times vary significantly, early reports document
ablation times using B-RFA which are magnitudes faster than
M-RFA. Yi et al. recently reported 26 consecutive B-RFA opera-
tions with an average ablation time of approximately 6 min, com-
pared with greater than 20 min using M-RFA.12,23 It was also the
authors’ experience that B-RFA was significantly faster than
M-RFA and required shorter ablation times. Ablation speed was
decreased because the systematic overlapping ablations lead to
rapid tumour/ parenchymal desiccation and contraction thereby
increasing current impedance.
Nevertheless, it must be mentioned that in the current series,
B-RFA had significantly longer operative times than M-RFA. This
is partly as a result of the learning curve associated with imple-
mentation of a novel device both for the surgeon as well as oper-
ating room ancillary staff. More importantly, B-RFA as a
treatment modality was generally reserved for tumours which
were more difficult to access and therefore required extensive
laparoscopic liver mobilization for proper probe positioning.
Additionally, as a result of tumour location, a significant number
of B-RFA patients underwent a concomitant cholecystectomy,
thereby also increasing operative time.
Laparoscopic treatment of liver tumours is becoming increas-
ingly utilized in most major medical centres. Laparoscopy pro-
vides improved visibility with a 2.5¥ magnification along with
several other well-established benefits such as decreased post-
operative pain, shortened hospital stay and earlier return to
work.24 Within the current series, adequate laparoscopic liver
mobilization was achieved in all patients. In addition, all tumours
were successfully treated using the 25 –cm-long dual B-RFA
probes regardless of location or patient body habitus. The less
invasive nature of laparoscopy allowed the treatment of older
patients with significant medical problems, patients withmarginal
hepatic reserve and those medically unfit for hepatic resection.
Within the current series of patients who underwent ablation
alone, only one patient experienced hepatic insufficiency post-
operatively, even although half had double-digit model for end-
stage liver disease (MELD) scores. Complications in this group
resulted from the need to place transdiaphragmatic, intercostal
ports for improved visualization of the hepatic veins. Two of these
patients underwent intra-operative thoracostomy tube placement
as prophylaxis against a clinically significant post-operative pneu-
mothorax. These tubes were removed post-operatively without
complication, and these patients as well as all others recovered
uneventfully from laparoscopic B-RFA. The presence of thoracos-
tomy tubes extended length of stay, which was significantly longer
than M-RFA. In part, the longer hospitalization documented in
this study was also related to the more recent referrals of out-of-
state veterans which occurred as the authors’ medical centre tran-
sitioned into a tertiary care facility for patients with liver tumours.
It is the institutional philosophy to ensure patients are completely
recovered before discharge, and often they are observed as an
inpatient for an extra day or two. In fact, many patients undergo
‘pre-emptive’ CT scanning to make sure they will not need further
interventions. In a veteran population, it has been shown previ-
ously that this type of referral practice pattern can prolong and
complicate discharge.25
Long-term follow-up of patients who underwent M-RFA and
B-RFA shows equivalency with respect to outcomes. Although
populations of each cohort are relatively small and follow-up less
than 3 years, there is still no difference between overall- and
disease-free survival (Fig. 4). Moreover, local and overall recur-
rence rates were likewise similar between the two modalities, as
was overall time to recurrence. Although this series had high local
recurrence rates, they are on par with local recurrence rates of
15%–28% reported in other small series with patients who under-
went M-RFA for unresectable HCC.26–29
The observed benefit of pre-coagulation – the ability to achieve
near-complete haemostasis at the planned resection plane – and
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the larger zone of coagulation with B-RFA adds important ben-
efits towards increasing the tumour-free margin. The synergistic
combination of pre-coagulation and laparoscopy gives the
surgeon the ability to complete a hepatic resection completely
laparoscopically with a decreased transfusion requirement and
conversion rate to laparotomy. Only two patients of the current
series required intra-operative blood transfusions. For patients
with impaired hepatic and functional reserve, the ability to
minimize the transfusion requirement and operative time has
significant benefits with respect to post-operative morbidity and
long-term survival.30
Although still controversial, hepatectomy in combination with
RFA in patients with multiple tumours is a viable option in
highly-selected patients.31 Given that the majority of our patients
were treated for HCC, many presented with multifocal disease.
Four of these patients underwent concomitant B-RFA for tumour
ablation as well as precoagulation of liver tissue before laparo-
scopic resection.Although small in number, these operations were
no more technically difficult than either procedure alone. More-
over, patients tolerated the concomitant procedures with no
greater morbidity or mortality, indicating another application of
B-RFA.
There are some important cautions that need to be stated
regarding probe deployment using the InCircleTM B-RFA device
for both tumour ablation and pre-coagulation. The design of the
parallel circular electrodes (Fig. 2) uses very thin ‘wiry’ tines that
can break and remain within the liver tissue. Moreover, if the
needles are positioned too closely and the tines make contact,
energy conduction will stop resulting in poor tissue coagulation
and bleeding. Rarely, the electrodes can arc and weld to the needle
exit side holes causing significant tissue damage and bleeding
when removed.
It should be emphasized that utilization of the InCircleTM
B-RFA device is best suited for those with proper knowledge of
hepatic anatomy. After the initial ultrasound-guided needle place-
ment, subsequent probe placement is done blindly within liver
parenchyma, increasing the risk of inadvertent injury to vascular
or biliary structures. Moreover, the lack of multiple terminal-
probe temperature sensors (as present in M-RFA) prevents real-
time assessment of improper probe placement. It is important not
only to consider the complete destruction of tissue between the
bipolar probes, but also the degree of lateral spread of the energy
(heat) that can cause delayed or unrecognized complications
(Fig. 5). For these reasons, B-RFA is ideally suited for experienced
hepatobiliary surgeons with thorough knowledge of internal liver
anatomy.
Nevertheless, once the surgeon gains experience using this
device, it can be safely used for both tumour ablation and/or for
Figure 5 Zone of ablation utilizing bipolar-radiofrequency ablation (B-RFA). Contrast-enhanced computed tomography (CT) scan of a
61-year-old patient with a 4.1-cm hepatocellular carcinoma (HCC) shown before ablation (a, arrow) and 3 months after the procedure (b).
A 71-year-old patient with multifocal HCC (c, arrows) with dual B-RFA ablation zones (d), shown 3 months after the procedure. The zone of
ablation with B-RFA encompasses large portions of liver parenchyma, necessitating expert knowledge of liver anatomy to avoid vital
structures
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precoagulation during hepatic resection. The ability to achieve
greater efficacy with the InCircleTM B-RFA energy delivery system
by laparoscopy, especially in the context of laparoscopic hepatic
resection, preserves the option of liver transplant and is an impor-
tant bridge to future therapies. Therefore, the promise of treating
patients with more advanced local disease and those with com-
promised hepatic reserve affords B- RFA an important adjunctive
role to hepatic surgery.
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